↓ Skip to main content

The Evolution of Aβ Peptide Burden in the APP23 Transgenic Mice: Implications for Aβ Deposition in Alzheimer Disease

Overview of attention for article published in Molecular Medicine, September 2001
Altmetric Badge

Citations

dimensions_citation
93 Dimensions

Readers on

mendeley
63 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The Evolution of Aβ Peptide Burden in the APP23 Transgenic Mice: Implications for Aβ Deposition in Alzheimer Disease
Published in
Molecular Medicine, September 2001
DOI 10.1007/bf03401867
Pubmed ID
Authors

Yu-Min Kuo, Thomas G. Beach, Lucia I. Sue, Sarah Scott, Kathryn J. Layne, Tyler A. Kokjohn, Walter M. Kalback, Dean C. Luehrs, Tatiana A. Vishnivetskaya, Dorothee Abramowski, Christine Sturchler-Pierrat, Matthias Staufenbiel, Roy O. Weller, Alex E. Roher

Abstract

High levels of A beta in the cerebral cortex distinguish demented Alzheimer's disease (AD) from nondemented elderly individuals, suggesting that decreased amyloid-beta (A beta) peptide clearance from the brain is a key precipitating factor in AD. The levels of A beta in brain and plasma as well as apolipoprotein E (ApoE) in brain were investigated by enzyme-linked immunosorbent assay (ELISA) and Western blotting at various times during the life span of the APP23 transgenic (Tg) and control mice. Histochemistry and immunocytochemistry were used to assess the morphologic characteristics of the brain parenchymal and cerebrovascular amyloid deposits and the intracellular amyloid precursor protein (APP) deposits in the APP23 Tg mice. No significant differences were found in the plasma levels of A beta between the APP23 Tg and control mice from 2-20 months of age. In contrast, soluble A beta levels in the brain were continually elevated, increasing 4-fold at 2 months and 33-fold in the APP23 Tg mice at 20 months of age when compared to the control mice. Soluble A beta42 was about 60% higher than A beta40. In the APP23 Tg mice, insoluble A beta40 remained at basal levels in the brain until 9 months and then rose to 680 microg/g cortex by 20 months. Insoluble A beta40 was negligible in non-Tg mice at all ages. Insoluble A beta42 in APP23 Tg mice rose to 60 microg/g cortex at 20 months, representing 24 times the control A beta42 levels. Elevated levels of ApoE in the brain were observed in the APP23 Tg mice at 2 months of age, becoming substantially higher by 20 months. ApoE colocalized with A beta in the plaques. Beta-amyloid precursor protein (betaAPP) deposits were detected within the neuronal cytoplasm from 4 months of age onward. Amyloid angiopathy in the APP23 Tg mice increased markedly with age, being by far more severe than in the Tg2576 mice. We suggest that the APP23 Tg mouse may develop an earlier blockage in A beta clearance than the Tg2576 mice, resulting in a more severe accumulation of A beta in the perivascular drainage pathways and in the brain. Both Tg mice reflect decreased A beta elimination and as models for the amyloid cascade they are useful to study AD pathophysiology and therapy.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 2%
Canada 1 2%
Australia 1 2%
Unknown 60 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 11 17%
Researcher 10 16%
Professor 9 14%
Student > Master 7 11%
Student > Bachelor 4 6%
Other 14 22%
Unknown 8 13%
Readers by discipline Count As %
Agricultural and Biological Sciences 22 35%
Medicine and Dentistry 11 17%
Neuroscience 7 11%
Biochemistry, Genetics and Molecular Biology 4 6%
Environmental Science 1 2%
Other 5 8%
Unknown 13 21%